Wordt geladen...
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal antibody yields durable responses in a subset of cancer patients and has been approved by the FDA as a standard therapy for late-stage melanoma. We recently identified inducible co-stimulator (ICOS) as a crucial player in the antit...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
The Rockefeller University Press
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3978270/ https://ncbi.nlm.nih.gov/pubmed/24687957 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20130590 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|